Back to top
more

Hims & Hers Health (HIMS)

(Delayed Data from NYSE)

$16.57 USD

16.57
8,793,432

+0.75 (4.74%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $16.55 -0.02 (-0.12%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

SenesTech (SNES) to Gain Market With Evolve's Launch on Amazon

SenesTech (SNES) looks to leverage the convenience and reach of e-commerce to expand its market share.

Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor

Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.

Reasons to Hold Charles River (CRL) in Your Portfolio Now

Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.

Moumi Mondal headshot

Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?

Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.

Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst

Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare

Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.

Here's Why Investors Should Retain ICON (ICLR) Stock Now

Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.

Stereotaxis (STXS) Gets CE Recertification for Approved Products

Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here's Why You Should Buy Boston Scientific (BSX) Stock Now

Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.

Charles River (CRL) Banks on RMS Growth Amid Competition

Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.

Zacks Market Edge Highlights: Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco

Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco are part of the Zacks Market Edge blog.

Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial

Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.

Reasons to Include Alcon (ALC) in Your Portfolio Right Now

New product launches and strong solvency bode well for Alcon (ALC).

Tracey Ryniec headshot

5 Top Ranked Strong Buy Growth Stocks for 2024

Get double digit earnings growth this year.

Boston Scientific (BSX) Rides on Emerging Markets, MedSurg

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care

Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.

Globus Medical (GMED) Hits 52-Week High: What's Driving It?

Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.

Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes

Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.

Here's Why You Should Buy Haemonetics (HAE) Stock Now

Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).

Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade

Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

Abbott's (ABT) share recovery in the Nutrition business buoys optimism.

IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues

IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.

Here's Why Investors Should Buy ResMed (RMD) Stock Now

Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.